15788-97-3

Upstream product

• 19438-10-9 methyl 3-hydroxybenzoate 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 
• 99-06-9 3-Carboxyphenol 
• 6304-89-8 3-acetoxybenzoic acid 
• 16446-73-4 3-(chlorocarbonyl)phenyl acetate 

Downstream Products

• 15504-63-9 3-Hydroxy-2,4,6-triiodo-N-methyl-benzamide 
• 1026438-64-1 3-[(6-(3-cyanophenoxy)-3,5-difluoro-4-methylpyridin-2-yl)oxy]-N-methylbenzenecarboxamide 
• 15504-91-3 4-(2,4,6-Triiodo-3-methylcarbamoyl-phenoxy)-butyric acid 
• 15504-74-2 2-(2,4,6-Triiodo-3-methylcarbamoyl-phenoxy)-butyric acid 
• 15504-86-6 2-(2,4,6-Triiodo-3-methylcarbamoyl-phenoxy)-hexanoic acid 
• 15504-80-0 Phenyl-(2,4,6-triiodo-3-methylcarbamoyl-phenoxy)-acetic acid 
• 1190089-97-4 C₂₃H₂₇N₃O₄ 
• 1279016-03-3 C₁₁H₁₃NO₃ 
• 1332302-40-5 3-((4-(3-(4-chloro-2-fluorophenoxy)azetidin-1-yl)-1,3,5-triazin-2-yl)oxy)-N-methylbenzamide 

Relevant academic research and scientific papers

NOVEL ULK1 INHIBITORS AND METHODS USING SAME

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

Thienopyrimidines as β3-adrenoceptor agonists: Hit-to-lead optimization

Resulting from a vHTS based on a pharmacophore alignment on known β3-adrenoceptor ligands, an aryloxypropanolamine scaffold comprising a thienopyrimidine moiety was further optimized as a human β3-AR agonist, yielding a lead compound with an excellent cellular activity of EC50 = 20 pM, selectivity over hβ1- and hβ2-adrenoceptors and a promising safety profile.

THIENOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS

Certain thienopyrimidine derivatives are useful for the inhibition of PDE10 enzymes, and thus are useful for treating psychiatric or neurological syndromes, e.g., pyschoses, obsessive-compulsive disorder and/or Parkinson's disease, as well as, for example

FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS

The invention relates to compounds of the formulae (I) to (III) wherein the substituents are as defined in the specification. These compounds have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Accordingly, the compounds of the formulae (I) to (III) would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmological conditions, proliferative diseases, inflammatory diseases, and other pathological conditions as described in the specification.